Axcella Announces Upcoming Oral Presentation at Digestive Disease Week (DDW) 2021

Abstracts are expected to appear on DDW\xe2\x80\x99s website in late April and in the May online supplement to Gastroenterology.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Thursday, April 22, 2021
Information
Tags: 
Health, Other Health, Other Science, Clinical trials, Research, Science, Biotechnology, Medical specialties, Hepatitis, Brain disorders, Clinical medicine, Anatomy, Hepatology, Steatohepatitis, Hepatic encephalopathy, Non-alcoholic fatty liver disease, Nash, Encephalopathy, Endogenous Metabolic Modulators (EMMs), Axcella, ENDOGENOUS METABOLIC MODULATORS (EMMS), AXCELLA
Geotags: 
United States, Massachusetts
⚠ generated by AI ↴
Summary
Key Points: 
  • Abstracts are expected to appear on DDW\xe2\x80\x99s website in late April and in the May online supplement to Gastroenterology.
  • ePosters and ePapers will be made available on this website during the congress.
  • The company\xe2\x80\x99s product candidates are comprised of EMMs and their derivatives that are engineered in distinct combinations and ratios to simultaneously impact multiple biological pathways.
  • Axcella\xe2\x80\x99s pipeline includes lead therapeutic candidates for non-alcoholic steatohepatitis (NASH) and the reduction in risk of overt hepatic encephalopathy (OHE) recurrence.


Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced the following upcoming oral presentation at the DDW 2021 regarding AXA1665, the company’s product candidate for the reduction in risk of recurrent overt hepatic encephalopathy (OHE):

  • Title: A Novel, Precision-Engineered Amino Acid Composition, AXA1665, is Safe, Well-Tolerated and Improves Neurocognition and Physical Function in Child-Pugh A and B Subjects

    Abstract Number: 848

    Presenter: Dr. Arun Sanyal, Professor in the Virginia Commonwealth University (VCU) Department of Internal Medicine and Education Core Director in the VCU Center for Clinical and Translational Research

    Session: #4450 Portal Hypertension

    Date/Time: Sunday, May 23rd from 5:45-6:00 p.m. ET

DDW 2021 is being held virtually from May 21 to 23, 2021. Abstracts are expected to appear on DDW’s website in late April and in the May online supplement to Gastroenterology. ePosters and ePapers will be made available on this website during the congress. DDW is the world’s leading educational forum for clinicians, researchers, students and trainees working in gastroenterology, hepatology, GI endoscopy, gastrointestinal surgery and related fields.

About Endogenous Metabolic Modulators (EMMs)

EMMs are a broad family of naturally occurring molecules, including amino acids, that regulate human metabolism. Axcella is developing a range of novel product candidates that are comprised of multiple EMMs engineered in distinct combinations and ratios to simultaneously impact multiple metabolic pathways to modify the underlying causes of various complex diseases and improve health.

Internet Posting of Information

Axcella uses its website, www.axcellahealth.com, as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Such disclosures will be included on the company’s website in the “Investors and News” section. Accordingly, investors should monitor this portion of the company’s website, in addition to following its press releases, SEC filings and public conference calls and webcasts.

About Axcella

Axcella is a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions. The company’s product candidates are comprised of EMMs and their derivatives that are engineered in distinct combinations and ratios to simultaneously impact multiple biological pathways. Axcella’s pipeline includes lead therapeutic candidates for non-alcoholic steatohepatitis (NASH) and the reduction in risk of overt hepatic encephalopathy (OHE) recurrence. For more information, please visit www.axcellahealth.com.

Copyright: 
Copyright Business Wire 2021